Bechara FG, Podda M, Prens EP, et al. - Researchers aimed at determining the efficacy and safety of adalimumab in conjunction with wide-excision surgery followed by secondary intention healing in adult patients with moderate to severe hidradenitis suppurativa (HS).

• The Safety and Efficacy of Adalimumab for Hidradenitis Suppurativa Peri-Surgically (SHARPS) trial is a randomized clinical trial involving 206 patients.

• HS clinical response was achieved across all body regions in significantly more patients receiving adalimumab vs placebo at week 12 along with significantly more improvements in quality of life.

• Patients with HS can be effectively managed using adalimumab, with no need to interrupt treatment prior to surgery.

• Considering these findings, medical treatment decisions can be made for cases with HS who are candidates for surgery.